BioWorld Asia

Oct. 1, 2008

Nitec Pharma Gets $22M to Fund Lodotra Launch

With a first European approval for its rheumatoid arthritis drug Lodotra imminent, Nitec Pharma AG raised CHF24 million (US$22 million) in a private equity round led by Munich, Germany-based TVM Capital. (BioWorld International) Read More

Telormedix Gets $19M in Series A Round

Elucidation of Cancer Growth Yields Potential Drug Targets

Nextech Closes Oncology Fund with $65M in Hand

Phynova Focusing on China, Pipeline and Conserving Cash

Genetically Modified Cotton is Good Neighbor to Other Crops

NicOx Signs Naproxcinod Agreement with Capsugel

ExonHit Therapeutics to Provide Genomic Services to French CRO

FDA Investigating Deaths in Ortho's German Stroke Trial

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for Dec. 27, 2024.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for December 24, 2024.

Illustration of neurons with Lewy bodies

Enhanced Cognition: Lewy body dementia phase II pumps stock

BioWorld

Investors will get more details during the International Lewy Body Dementia Conference in Amsterdam late next month, but Wall Street is already buzzing about...

Experimental mRNA gene therapy suppresses preeclampsia in mice

BioWorld MedTech

A gene therapy based on an enhanced lipid nanoparticle (LNP) loaded with vascular endothelial growth factor (VEGF) mRNA could be developed for the treatment of...

Lab glassware and antibodies art concept

Probing bidirectional cancer-autoimmune link can yield new targets

BioWorld Science

Cancer and autoimmunity are “often thought of as being at opposite ends of the immune response,” Ana Anderson told her audience at a joint meeting of the NIH’s...